Genomic alterations potentially targetable with precision therapeutics uniquely present in the rare CNS and extracranial solid tumors include ERBB2 activating mutations in carcinomas, KIT activating mutations in CNS and non-CNS germ cell tumors, and CTNNB1 inactivating mutations in carcinomas, liver tumors, desmoid tumors, and craniopharyngiomas (Fig. 6). This evidence concerns the gene ERBB2 and germ cell tumor.